Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 86Bevacizumab 66Capecitabine 65Fluorouracil 48tislelizumab 41Gemcitabine 40Drug Therapy 39Leucovorin 38sintilimab 35Irinotecan 34lenvatinib 27Cisplatin 27HMPL-013 25S 1 (combination) 23camrelizumab 22Immune Checkpoint Inhibitors 21irinotecan sucrosofate 20apatinib 20Surgical Procedures, Operative 20Radiotherapy 20Injections 20130-nm albumin-bound paclitaxel 20toripalimab 19Paclitaxel 18Folfox protocol 17pembrolizumab 15Immunotherapy 15Cetuximab 15Specimen Handling 14regorafenib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ondansetron × Gastrointestinal × Clear all
NCT07381634 2026-03-11

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
134 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡